Liliane Michaliks’ group further showed that the PPARγ agonist rosiglitazone activates a tumorigenic secretion program of cytokines, chemokines, and pro-angiogenic factors in melanoma cells, leading to a tumor progression- and metastasis-favoring microenvironment [267]. Here, PPARG is linked to melanoma.